Efficacy and Safety of PD-1/PD-L1 Inhibitor Chemotherapy Combined with Lung Cancer Fang No. 1 in Relapsed and Refractory SCLC: A Retrospective Observational Study

BACKGROUND: Relapsed and refractory small cell lung cancer (SCLC) accounts for about 15% of all lung cancers. The prognosis of patients is poor. The 5-year survival rate is almost 0. The average survival time of patients who refuse to receive treatment is only 2-4 months. For patients with extensive...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Lihua, Lei, Xiaoxia, Wang, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110176/
https://www.ncbi.nlm.nih.gov/pubmed/35586668
http://dx.doi.org/10.1155/2022/2848220

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9110176/
https://www.ncbi.nlm.nih.gov/pubmed/35586668
http://dx.doi.org/10.1155/2022/2848220

Ejemplares similares